Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: One-year analysis

Schizophrenia Research

Volumn 93, Issue 1-3, 2007, Pages 90-98

  Strassnig, Martin ^a   Miewald, Jean ^a   Keshavan, Matcheri ^b   Ganguli, Rohan ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

Antidepressants; Antipsychotics; First episode psychosis; Obesity; Predictors; Schizophrenia; Weight gain; Weight gain prevention

Indexed keywords

ANTIHISTAMINIC AGENT; ARIPIPRAZOLE; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; FLUPHENAZINE; HALOPERIDOL; HYPNOTIC AGENT; LITHIUM; LOXAPINE; OLANZAPINE; PERPHENAZINE; PROPRANOLOL; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; THIORIDAZINE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID; ZIPRASIDONE;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CALCULATION; CONFOUNDING VARIABLE; CONTROLLED STUDY; DRUG EFFECT; DRUG SUBSTITUTION; FEMALE; FOLLOW UP; HEALTH HAZARD; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOSIS; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; WEIGHT GAIN;

ADULT; AFFECTIVE DISORDERS, PSYCHOTIC; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BODY MASS INDEX; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HALOPERIDOL; HUMANS; MALE; PERPHENAZINE; PSYCHIATRIC STATUS RATING SCALES; REFERENCE VALUES; RISPERIDONE; SCHIZOPHRENIA; WEIGHT GAIN;

EID: 34249331312     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2007.02.024     Document Type: Article

References (47)

1. Addington J., Mansley C., and Addington D. Weight gain in first-episode psychosis. Can. J. Psychiatry 48 4 (2003) 272-276
2. Allison D.B., Fontaine K.R., Heo M., Mentore J.L., Cappelleri J.C., Chandler L.P., Weiden P.J., and Cheskin L.J. The distribution of body mass index among individuals with and without schizophrenia. J. Clin. Psychiatry 60 4 (1999) 215-220
3. Andreasen N.C. The Scale for the Assessment of Negative Symptoms (SANS): conceptual and theoretical foundations. Br. J. Psychiatry Suppl. (1989) 49-58
4. Andreasen N.C. Methods for assessing positive and negative symptoms. Mod. Probl. Pharmacopsychiatry 24 (1990) 73-88
5. Ball K., and Crawford D. Socioeconomic status and weight change in adults: a review. Soc. Sci. Med. 60 9 (2005) 1987-2010
6. Brar J.S., Ganguli R., Pandina G., Turkoz I., Berry S., and Mahmoud R. Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder. J. Clin. Psychiatry 66 2 (2005) 205-212
7. Brown S., Birtwistle J., Roe L., and Thompson C. The unhealthy lifestyle of people with schizophrenia. Psychol. Med. 29 3 (1999) 697-701
8. Coldham E.L., Addington J., and Addington D. Medication adherence of individuals with a first episode psychosis. Acta Psychiatr. Scand. 106 (2002) 286-290
9. Daumit G.L., Crum R.M., Guallar E., Powe N.R., Primm A.B., Steinwachs D.M., and Ford D.E. Outpatient prescriptions for atypical antipsychotics for African Americans, Hispanics and Whites in the United States. Arch. Gen. Psychiatry 60 (2003) 121-128
10. Faulkner G., Soundy A.A., and Lloyd K. Schizophrenia and weight management: a systematic review of interventions to control weight. Acta Psychiatr. Scand. 108 (2003) 324-332
11. First M.B., Spitzer R.L., Gibbon M., and Williams J.B.W. Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version (SCID-CV) (1996), American Psychiatric Press, Washington DC
12. Ganguli R., and Strassnig M. Are older antipsychotic drugs obsolete. Br. Med. J. 332 (2006) 1346-1347
13. Ganguli R. Weight gain associated with antipsychotics. J. Clin. Psychiatry 60 suppl 21 (1999) 20-24
14. Ganguli R., Brar J.S., and Ayrton Z. Weight gain over 4 months in schizophrenia patients: a comparison of olanzapine and risperidone. Schizophr. Res. 49 (2001) 261-267
15. Ganguli R., and Brar J.S. Prevention of Weight gain, by behavioral interventions, in patients starting novel antipsychotics. Schizophr. Bull. 31 2 (2005) 561-562
16. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 23 (1960) 56-62
17. Helgason L. Twenty years' follow up of first psychiatric presentation for schizophrenia: what could have been prevented?. Acta Psychiatr. Scand. 81 (1990) 231-235
18. Henderson D.C., Cagliero E., Gray C., Nasrallah R.A., Hayden D.L., Schoenfeld D.A., and Goff D.C. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. Am. J. Psychiatry 157 6 (2000) 975-981
19. Hollingshead A.B. Four Factor Index of Social Status (1975), New Haven, CT 1-22
20. Homel P., Casey D., and Allison D.B. Changes in body mass index for individuals with and without schizophrenia, 1987-1996. Schizophr. Res. 55 3 (2002) 277-284
21. Kelly D.L., Conley R.R., and Carpenter W.T. First-episode schizophrenia. A focus on pharmacological treatment and safety considerations. Drugs 65 8 (2005) 1113-1138
22. Johnson D.B., Gerstein D.E., Evans A.E., and Woodward-Lopez G. Preventing obesity: a life cycle perspective. J. Am. Diet. Assoc. 106 1 (2006) 97-102
23. Kinon B.J., Basson B.R., Gilmore J.A., and Tollefson G.D. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J. Clin. Psychiatry 62 2 (2001) 92-100
24. Lieberman J.A. Atypical antipsychotic drugs as a first-line treatment of schizophrenia. J. Clin. Psychiatry 57 suppl 11 (1996) 68-71
25. Lieberman J.A., Sheitman B., Chakos M., Robinson D., Schooler N., and Keith S. The development of treatment resistance in patients with schizophrenia: a clinical and pathophysiological perspective. J. Clin. Psychopharmacol. 18 (1998) S20-S24
26. Lieberman J.A., Phillips M., Gu H., Stroup S., Zhang P., Kong L., Ji J., Koch G., and Hamer R.M. Atypical and conventional antipsychotic drugs in treatment-naïve first-episode schizophrenia: a 52-week randomized trial of clozapine vs. chlorpromazine. Neuropsychopharmacology 28 5 (2003) 995-1003
27. Marder S.R., Essock S.M., Miller A.L., Buchanan R.W., Casey D.E., Davis J., Kane J.M., Lieberman J.A., Schooler N.R., Covell N., Stroup S., Weissman E.M., Wirshing D.A., Hall C.S., Pogach L., Pi-Sunyer X., Bigger Jr. J.T., Friedman A., Kleinberg D., Yevich S.J., Davis B., and Shon S. Physical health monitoring of patient with schizophrenia. Am. J. Psychiatry 161 8 (2004) 1334-1349
28. McEvoy J.P., Hogarty G.E., and Steingard S. Optimal dose of neuroleptic in acute schizophrenia. Arch. Gen. Psychiatry 48 (1991) 739-745
29. McEvoy J.P., Meyer J.M., Goff D.C., Nasrallah H.A., Davis S.M., Sullivan L., Meltzer H.Y., Hsiao J., Stroup T.S., and Lieberman J.A. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr. Res. 80 (2005) 19-32
30. Meyer J.M., Nasrallah H.A., McEvoy J.P., Goff D.C., Davis S.M., Chakos M., Patel J.K., Keefe R.S.E., Stroup T.S., and Lieberman J.A. The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome. Schizophr. Res. 80 (2005) 9-18
31. Nakayama K.M. Body weight induced by a newer antipsychotic agent reversed as negative symptoms improved. Acta Psychiatr. Scand. 112 (2005) 75-77
32. National Task Force on the Prevention and Treatment of Obesity. Overweight, obesity and health risk. Arch. Intern. Med. 160 7 (2000) 898-904
33. Osby U., Correia N., Brandt L., Ekbom A., and Sparen P. Mortality and causes of death in schizophrenia in Stockholm County, Sweden. Schizophr. Res. 45 1-2 (2000) 21-28
34. Poirier P., Giles T.D., Bray G.A., Hong Y., Stern J.S., Pi-Sunyer F.X., and Eckel R.H. Arterioscler. Thromb. Vasc. Biol. 26 5 (2006) 968-976
35. Ratzoni G., Gothelf D., Brand-Gothelf A., Reidman J., Kikinzon L., Gal G., Phillip M., Apter A., and Weizman R. Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. J. Am. Acad. Child. Adolesc. Psychiatry 41 3 (2002) 337-343
36. Robinson D., Woerner M.G., Alvir J.M., Bilder R.M., Hinrichsen G.A., and Lieberman J.A. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch. Gen. Psychiatry 56 (1999) 241-247
37. Russell J.M., and Mackell J.A. Bodyweight gain associated with atypical antipsychotics: epidemiology and therapeutic implications. CNS Drugs 15 7 (2001) 537-551
38. Ryan M.C., and Thakore J.H. Physical consequences of schizophrenia and its treatment: the metabolic syndrome. Life Sci. 71 3 (2002) 239-257
39. Strassnig M., Brar J.S., and Ganguli R. Nutritional assessment of patients with schizophrenia: a preliminary study. Schizophr. Bull. 29 2 (2003) 393-397
40. Strassnig M., Brar J.S., and Ganguli R. Body mass index and quality of life in community-dwelling patients with schizophrenia. Schizophr. Res. 62 1-2 (2003) 73-76
41. Strassnig M., Brar J.S., and Ganguli R. Self-reported body weight perception and dieting practices in community-dwelling patients with schizophrenia. Schizophr. Res. 75 2-3 (2005) 425-432
42. Thakore J.H. Metabolic disturbance in first-episode schizophrenia. Br. J. Psychiatry 184 suppl 47 (2004) s76-s79
43. Van Mastrigt S., Addington J., and Addington D. Substance misuse at presentation to an early psychosis program. Soc. Psychiatry Psychiatr. Epidemiol. 39 (2004) 69-72
44. Weiden P., and Mackell J. Differing side effect burden with newer antipsychotics. Eur. Neuropsychopharmacol. 9 suppl 5 (1999) S266
45. Weiss R., Dziura J., Burgert T.S., Tamborlane W.V., Taksali S.E., Yeckel C.W., Allen K., Lopes M., Savoye M., Morrison J., Sherwin R.S., and Caprio S. Obesity and the metabolic syndrome in children and adolescents. N. Engl. J. Med. 350 23 (2004) 2362-2374
46. Yan L.L., Daviglus M.L., Liu K., Stamler J., Wang R., Pirzada A., Garside D.B., Dyer A.R., Van Horn L., Liao Y., Fries J.F., and Greenland P. Midlife body mass index and hospitalization and mortality in older age. JAMA 295 (2006) 190-198
47. Zipursky R.B., Gu H., Green A.I., Perkins D.O., Tohen M.F., McEvoy J.P., Strakowski S.M., Sharma T., Kahn R.S., Gur R.E., Tollefson G.D., and Lieberman J.A. Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br. J. Psychiatry 187 (2005) 537-543